Glenmark & Bausch enter agreement to commercialize Ryaltris in Canada
Category: #health  By Pankaj Singh  Date: 2021-03-23
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Glenmark & Bausch enter agreement to commercialize Ryaltris in Canada

Glenmark Pharmaceuticals, a pharmaceutical company, has recently entered an agreement with Bausch, an eye health products company, to commercialize Ryaltris, its nasal spray in Canada.

For those uninitiated, Switzerland-based Glenmark Specialty SA, a subsidiary of Glenmark, and an affiliate of Bausch Health have signed an exclusive licensing deal to commercialize Glenmark’s Ryaltris that is presently under review by Health Canada. As per the terms of the agreement, the Mumbai-based company will be in charge of the regulatory approvals as well as the supply of this nasal spray in the Canadian market. On the other hand, Bausch Health will be responsible for the product commercialization in the region following the regulatory approvals.

According to reliable reports, apart from the royalties & supply price from product sales, Glenmark will also receive an upfront payment and launch & sales-based milestone payments. Moreover, the agreement will last for ten years and has an option to renew. Currently, Health Canada is reviewing Ryaltris with a proposed indication for treating seasonal allergic rhinitis among adults and children of over 12 years.

Sanjeev Krishan, North America President & Business Head at Glenmark Pharmaceuticals, has reportedly cited that the company is thrilled to collaborate with Bausch Health Canada, which has been maintaining a robust footprint in the prescription & OTC market in Canada. This latest agreement will help it cater to a large patient base and extend the numerous benefits of Ryaltris to a key market, he added.

As per the statement made by the President of Bausch Health, Canada, Richard Lajoie, the company is excited to expand its allergy product portfolio via the addition of Ryaltris and make it available across Canada to treat patients with allergies.

On the Bombay Stock Exchange, Glenmark’s shares were trading at ₹459.80 ($6.36) per scrip, a hike of 0.24% from the previous close.

Source credit:

https://www.moneycontrol.com/news/business/glenmark-joins-hands-with-bausch-to-commercialise-nasal-spray-in-canada-6676801.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

MGMA partners with WhiteSpace Health to unveil MGMA DataDiscovery tool

MGMA partners with WhiteSpace Health to unveil MGMA DataDiscovery tool

By Pankaj Singh

Well-known medical practice management organization, Medical Group Management Association (MGMA) has reportedly joined forces with WhiteSpace Health to release a new medical group analytics tool, MGMA DataDiscovery. Th...

Santex acquires U.S. online retailer Parentgiving for market expansion

Santex acquires U.S. online retailer Parentgiving for market expansion

By Pankaj Singh

Italy-based personal care and incontinence product manufacturer Santex SPA has reportedly acquired Parentgiving Inc., America’s top-rated e-commerce retailer of geriatric care products.

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

By Pankaj Singh

La Samaritaine, a historic landmark of 19th century France, has been reportedly revamped as a new destination for dining, all-in-one shopping, and tourism by LVMH, a French luxury conglomerate. The stores&rs...